• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异柠檬酸脱氢酶（IDH）突变型髓系肿瘤与血清阴性类风湿性关节炎及固有免疫激活相关。

IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.

作者信息

Hong Lih En, Wechalekar Mihir D, Kutyna Monika, Small Annabelle, Lim Kelly, Thompson-Peach Chloe, Li Joule J, Chhetri Rakchha, Scott Hamish S, Brown Anna, Hahn Christopher N, Yeung David T, Sajid Salvia, Robinson Nirmal, Thomas Ranjeny, Branford Susan, D'Andrea Richard J, Samaraweera Saumya E, Patnaik Mrinal, Proudman Susanna, Thomas Daniel, Kok Chung Hoow, Shah Mithun V, Hiwase Devendra K

机构信息

Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia.

Adelaide Medical School, University of Adelaide, Adelaide, Australia.

出版信息

Blood. 2024 May 2;143(18):1873-1877. doi: 10.1182/blood.2023023593.

DOI:10.1182/blood.2023023593
PMID:38457663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11076852/
Abstract

High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.

摘要

在伴有髓系肿瘤、2-羟基戊二酸升高、先天免疫失调和促炎微环境的血清阴性类风湿性关节炎（RA）中，异柠檬酸脱氢酶（IDH）突变的高发生率表明IDH突变与血清阴性RA之间存在因果关联。我们的研究结果值得对IDH抑制剂作为血清阴性IDH突变型RA的治疗方法进行研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c618/11076852/bac32b13565b/BLOOD_BLD-2023-023593-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c618/11076852/67d1284c1baf/BLOOD_BLD-2023-023593-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c618/11076852/bac32b13565b/BLOOD_BLD-2023-023593-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c618/11076852/67d1284c1baf/BLOOD_BLD-2023-023593-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c618/11076852/bac32b13565b/BLOOD_BLD-2023-023593-gr2.jpg

相似文献

1
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.异柠檬酸脱氢酶（IDH）突变型髓系肿瘤与血清阴性类风湿性关节炎及固有免疫激活相关。
Blood. 2024 May 2;143(18):1873-1877. doi: 10.1182/blood.2023023593.
2
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.异柠檬酸脱氢酶（IDH）突变型胶质瘤中尿2-羟基戊二酸水平升高
Oncologist. 2016 Feb;21(2):214-9. doi: 10.1634/theoncologist.2015-0342. Epub 2016 Feb 1.
3
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.异柠檬酸脱氢酶2突变的母细胞样浆细胞样树突状细胞肿瘤中血浆d-2-羟基戊二酸水平升高。
Hum Pathol. 2015 Feb;46(2):322-6. doi: 10.1016/j.humpath.2014.10.013. Epub 2014 Nov 4.
4
Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.去分化软骨肉瘤中异柠檬酸脱氢酶 1/异柠檬酸脱氢酶 2 基因突变和 d-2-羟戊酸致癌代谢物水平的特征。
Histopathology. 2020 Apr;76(5):722-730. doi: 10.1111/his.14018. Epub 2020 Mar 10.
5
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.伴有 FLT3-ITD 和 IDH 突变的急性髓系白血病患者的临床特征和结局。
Cancer. 2021 Feb 1;127(3):381-390. doi: 10.1002/cncr.33293. Epub 2020 Oct 29.
6
Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.2-羟戊二酸的积累不是 IDH 突变型低级别胶质瘤恶性进展的生物标志物。
Neuro Oncol. 2013 Jun;15(6):682-90. doi: 10.1093/neuonc/not006. Epub 2013 Feb 14.
7
Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.在临床环境中通过磁共振波谱技术无创评估脑胶质瘤异柠檬酸脱氢酶基因突变状态。
J Neurosurg. 2018 Feb;128(2):391-398. doi: 10.3171/2016.10.JNS161793. Epub 2017 Mar 3.
8
Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.脑胶质瘤异柠檬酸脱氢酶突变的免疫治疗潜力进展。
Neurosci Bull. 2022 Sep;38(9):1069-1084. doi: 10.1007/s12264-022-00866-1. Epub 2022 Jun 7.
9
[Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].[异柠檬酸脱氢酶基因突变的成人急性髓系白血病的临床特征]
Zhonghua Yi Xue Za Zhi. 2013 Mar 12;93(10):751-5.
10
IDH mutations in cancer and progress toward development of targeted therapeutics.癌症中的异柠檬酸脱氢酶（IDH）突变与靶向治疗药物研发进展
Ann Oncol. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013.

引用本文的文献

1
Current state and future directions of basic research in rheumatoid arthritis.类风湿关节炎基础研究的现状与未来方向
J Rheum Dis. 2025 Jul 1;32(3):166-181. doi: 10.4078/jrd.2024.0151. Epub 2025 Feb 6.
2
SPAG11B, a potential biomarker for rheumatoid arthritis: a two-sample bidirectional Mendelian randomization analysis.SPAG11B，类风湿性关节炎的一种潜在生物标志物：一项两样本双向孟德尔随机化分析
BMC Rheumatol. 2025 Jun 4;9(1):65. doi: 10.1186/s41927-025-00521-y.
3
Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes.

本文引用的文献

1
IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation.异柠檬酸脱氢酶1（IDH1）突变的白血病前期造血干细胞可通过抑制氧化磷酸化作用而被清除。
Blood Cancer Discov. 2023 Dec 13;5(2):114-31. doi: 10.1158/2643-3230.BCD-23-0195.
2
The longitudinal dynamics and natural history of clonal haematopoiesis.克隆性造血的纵向动力学和自然史。
Nature. 2022 Jun;606(7913):335-342. doi: 10.1038/s41586-022-04785-z. Epub 2022 Jun 1.
3
Ivosidenib and Azacitidine in -Mutated Acute Myeloid Leukemia.ivosidenib 和阿扎胞苷治疗 - 突变型急性髓系白血病。
基于血液的蛋白质组学分析确定OSMR为急性髓系白血病预后的新型生物标志物。
Blood. 2025 Jun 19;145(25):3015-3029. doi: 10.1182/blood.2024027244.
4
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.急性髓系白血病异基因移植前可测量的残留突变型异柠檬酸脱氢酶2
Bone Marrow Transplant. 2025 Feb;60(2):144-153. doi: 10.1038/s41409-024-02449-2. Epub 2024 Oct 25.
N Engl J Med. 2022 Apr 21;386(16):1519-1531. doi: 10.1056/NEJMoa2117344.
4
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.依尼西尼（enasidenib）联合阿扎胞苷对比阿扎胞苷单药治疗新诊断、突变型 IDH2 急性髓系白血病患者（AG221-AML-005）：一项单臂、1b 期和随机、2 期试验。
Lancet Oncol. 2021 Nov;22(11):1597-1608. doi: 10.1016/S1470-2045(21)00494-0. Epub 2021 Oct 18.
5
Somatic Mutations and the Risk of Undifferentiated Autoinflammatory Disease in MDS: An Under-Recognized but Prognostically Important Complication.骨髓增生异常综合征中未分化自身炎症性疾病的体细胞突变和风险：一种被低估但具有重要预后意义的并发症。
Front Immunol. 2021 Feb 19;12:610019. doi: 10.3389/fimmu.2021.610019. eCollection 2021.
6
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease.与全身炎症和自身免疫性疾病相关的骨髓增生异常综合征/慢性粒单核细胞白血病的基因组图谱。
Leukemia. 2021 Sep;35(9):2720-2724. doi: 10.1038/s41375-021-01152-1. Epub 2021 Feb 23.
7
Somatic Mutations in and Severe Adult-Onset Autoinflammatory Disease.和严重成人发病的自身炎症性疾病中的体细胞突变。
N Engl J Med. 2020 Dec 31;383(27):2628-2638. doi: 10.1056/NEJMoa2026834. Epub 2020 Oct 27.
8
Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma.人异柠檬酸脱氢酶（IDH）突变型和野生型胶质母细胞瘤中不同的小胶质细胞和巨噬细胞特征
Oncotarget. 2019 May 3;10(33):3129-3143. doi: 10.18632/oncotarget.26863.
9
Autoimmune diseases and myelodysplastic syndromes.自身免疫性疾病和骨髓增生异常综合征。
Am J Hematol. 2016 May;91(5):E280-3. doi: 10.1002/ajh.24333. Epub 2016 Apr 4.
10
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.与骨髓增生异常综合征和慢性粒单核细胞白血病相关的全身炎症和自身免疫表现：一项法国多中心回顾性研究。
Rheumatology (Oxford). 2016 Feb;55(2):291-300. doi: 10.1093/rheumatology/kev294. Epub 2015 Sep 8.